PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY TYPE Market segmentation by type Comparison by type Non-hormonal therapy - Market size and forecast 2018-2023 Hormonal therapy - Market size and forecast 2018-2023 Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increasing R&D for treatment of sexual dysfunctions in women Safety label changes for female sexual dysfunction therapy Increasing use of drugs causing sexual dysfunctions in women PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AMAG Pharmaceuticals Inc. Duchesnay Inc. Emotional Brain BV Novo Nordisk AS Sprout Pharmaceuticals Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Type - Market share 2018-2023 (%) Exhibit 18: Comparison by type Exhibit 19: Non-hormonal therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Non-hormonal therapy - Year-over-year growth 2019-2023 (%) Exhibit 21: Hormonal therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Hormonal therapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Market opportunity by type Exhibit 24: Customer landscape Exhibit 25: Market share by geography 2018-2023 (%) Exhibit 26: Geographic comparison Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 28: North America - Year-over-year growth 2019-2023 (%) Exhibit 29: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 30: Europe - Year-over-year growth 2019-2023 (%) Exhibit 31: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Asia - Year-over-year growth 2019-2023 (%) Exhibit 33: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 34: ROW - Year-over-year growth 2019-2023 (%) Exhibit 35: Key leading countries Exhibit 36: Market opportunity Exhibit 37: Impact of drivers and challenges Exhibit 38: Vendor landscape Exhibit 39: Landscape disruption Exhibit 40: Vendors covered Exhibit 41: Vendor classification Exhibit 42: Market positioning of vendors Exhibit 43: AMAG Pharmaceuticals Inc. - Vendor overview Exhibit 44: AMAG Pharmaceuticals Inc. - Business segments Exhibit 45: AMAG Pharmaceuticals Inc. - Organizational developments Exhibit 46: AMAG Pharmaceuticals Inc. - Key offerings Exhibit 47: Duchesnay Inc. - Vendor overview Exhibit 48: Duchesnay Inc. - Key offerings Exhibit 49: Emotional Brain BV - Vendor overview Exhibit 50: Emotional Brain BV - Key offerings Exhibit 51: Novo Nordisk AS - Vendor overview Exhibit 52: Novo Nordisk AS - Business segments Exhibit 53: Novo Nordisk AS - Organizational developments Exhibit 54: Novo Nordisk AS - Geographic focus Exhibit 55: Novo Nordisk AS - Segment focus Exhibit 56: Novo Nordisk AS - Key offerings Exhibit 57: Sprout Pharmaceuticals Inc. - Vendor overview Exhibit 58: Sprout Pharmaceuticals Inc. - Key offerings Exhibit 59: Validation techniques employed for market sizing Exhibit 60: Definition of market positioning of vendors  

AMAG Pharmaceuticals Inc., Duchesnay Inc., Emotional Brain BV, Novo Nordisk AS, and Sprout Pharmaceuticals Inc.